News
12-10-2010, 08:30 AM
New data presented at the CTRC-AACR 33rd Annual San Antonio Breast Cancer Symposium, USA, suggest fulvestrant 500mg offers improved disease control compared with the aromatase inhibitor, anastrozole, when used as a first-line treatment* for hormone receptor positive breast cancer...
More... (http://mnt.to/f/3NSq)
More... (http://mnt.to/f/3NSq)